Two stocks in Drug Manufacturers - General
Bristol-Myers Squibb vs Johnson & Johnson: profit, growth, debt and price compared
Bristol-Myers Squibb is stronger on 4 of 7 figures: profit margin, sales growth, price for its expected profit and dividend. Johnson & Johnson is stronger on 2: debt and price trend.
Save both stocks to your watchlist and revisit their latest fundamentals.
| Bristol-Myers SquibbBMY | Johnson & JohnsonJNJ | |
|---|---|---|
| Net margin | Stronger: 18.5% | 16.2% |
| Revenue growth, past year | Stronger: +6.93% | +5.86% |
| Debt to equity | 191.5% | Stronger: 54.8% |
| Forward P/E | Stronger: 8.9× | 23.5× |
| Dividend yield | Stronger: 4.23% | 1.94% |
| Analysts | Buy · 24 | Buy · 22 |
| From its 200-day average | +1.2% | Stronger: +10.2% |
Share price over the past year
- Bristol-Myers Squibb+26.6%
- Johnson & Johnson+36.3%
18 Nov 202518 Nov 2026
Bristol-Myers Squibb or Johnson & Johnson: which is stronger?
- BMY
Which is more profitable?
Bristol-Myers Squibb keeps more of each sale as profit: 18.5% against 16.2%.
- BMY
Which is growing its sales faster?
Bristol-Myers Squibb is growing its sales faster: +6.93% over the past year, against +5.86%.
- JNJ
Which has borrowed less?
Johnson & Johnson has borrowed less: its debt is 54.8% of what its shareholders own, against 191.5% for Bristol-Myers Squibb.
- BMY
Which costs less for the profit it is expected to make?
Bristol-Myers Squibb costs less for the profit it is expected to make: 8.9× its forward earnings, against 23.5×.
- BMY
Which pays more in dividends?
Bristol-Myers Squibb pays more back in dividends for what a share costs: 4.23% a year, against 1.94%.
Which do analysts rate higher?
Analysts rate both the same: Buy.
- JNJ
Which is in the stronger price trend?
Johnson & Johnson's price is in the stronger trend: 10.2% above its 200-day average, against 1.2% above.
What each company does
BMYBristol-Myers Squibb
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide.
Reports results on 4 February 2027
JNJJohnson & Johnson
Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide.
Reports results on 26 January 2027
This comparison is just the starting point.
Discover opportunities, understand companies and compare investments in one place. See how StratDeck works
Keep researching
Where next
More comparisons
Free email
Up to speed in minutes, four times a week
Every Monday, know what moved AI stocks and what to watch next. Every Wednesday and Friday, find a stock worth a look and learn its story. Every Sunday, catch up on the market's week in two minutes.
Early access
Become a StratDeck founding user
Use StratDeck, tell us what's missing, and help decide what we build next.
100 founding places. Founding users get their first month free, then half price for life: £2.99 a month or £30 a year.